Form 4: Damora Therapeutics CEO Jarrett Acquires Equity

Damora Therapeutics' President and CEO, Jennifer Jarrett, acquired 500,000 restricted stock units and 1,500,000 stock options on March 30, 2026.

Summary

• Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics, Inc. (DMRA), acquired 500,000 shares of common stock in the form of Restricted Stock Units (RSUs) on March 30, 2026.
• Each RSU represents the right to receive one share of common stock and will vest 25% on each anniversary of the grant date through the fourth anniversary, contingent on continued service.
• Jarrett also acquired 1,500,000 stock options with an exercise price of $25.5 per share on March 30, 2026.
• These stock options will vest 25% on March 30, 2027, and in equal monthly installments thereafter through March 30, 2030, also subject to continued service.
• The options have an expiration date of March 30, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strong alignment between executive leadership and shareholder interests through significant equity grants, which can foster long-term commitment and performance.

Positives

• The acquisition of significant equity (RSUs and stock options) by the President and CEO, Jennifer Jarrett, demonstrates strong alignment of management's interests with those of shareholders.
• The long-term vesting schedules for both RSUs (four years) and stock options (three years) incentivize sustained performance and commitment to the company's long-term success.

Negatives

• The grants are future-oriented and do not represent an immediate cash investment by the insider, which might be seen as a stronger signal of confidence.

Risks

• The vesting of both RSUs and stock options is contingent upon the Reporting Person's continued service to the Issuer, meaning the benefits are not guaranteed if employment ceases.

Future Outlook

The equity grants to the CEO are designed to align her long-term financial incentives with the company's performance and shareholder value creation over the next several years, with vesting periods extending up to four years for RSUs and three years for stock options.

Industry Context

StockSavvy.ai notes that significant equity grants to executive leadership, particularly the CEO, are a standard practice across industries, especially in growth-oriented sectors like biotechnology or pharmaceuticals where long-term value creation is paramount. This strategy aims to incentivize executives to drive sustained growth and align their financial success directly with the company's stock performance.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and stock options with multi-year vesting schedules, is a common and widely accepted practice for executive compensation in publicly traded companies, particularly within the biotech and pharmaceutical sectors.
• The structure of 25% annual vesting over four years for RSUs and a similar multi-year vesting for options is typical for aligning executive incentives with long-term shareholder value, comparable to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their key executives.

Management Changes

Stakeholder Impact

• Shareholders: The equity grants align the CEO's financial incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: The CEO's long-term commitment, as signaled by these grants, may contribute to stability and strategic direction within the company.

Next Steps

• Jennifer Jarrett's continued service to Damora Therapeutics is required for the vesting of her Restricted Stock Units and stock options.
• The RSUs will vest 25% annually on the grant date anniversary over four years.
• The stock options will begin vesting 25% on March 30, 2027, and continue in equal monthly installments through March 30, 2030.

Key Dates

Keywords

Damora Therapeutics, DMRA, Jennifer Jarrett, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, CEO Compensation, Equity Grant